Key Findings from this Session
- Analysis of 3,217 KRAS/NRAS/BRAF wild-type left-sided CRCs profiled by Caris showed that HER2-mutated tumors had worse outcomes following anti-EGFR therapy than HER2-normal tumors, whereas HER2-amplified tumors showed no significant difference in overall survival.
- This study demonstrate how comprehensive molecular profiling can identify clinically meaningful genomic subgroups in colorectal cancer, enabling biomarker discovery and refinement of targeted treatment strategies.